Researchers found that GLP-1 receptor agonists (GLP-1RAs) — drugs widely used to treat type 2 diabetes — can reduce Alzheimer's disease (AD) features in transgenic mice by activating the AMPK energy-sensing pathway. The study showed that GLP-1 levels are lower in AD model mice and inversely linked to amyloid-beta (Aβ) burden in human AD patients. GLP-1RAs boosted CaMKK2-AMPK signaling, which cut BACE1 enzyme activity, reducing harmful Aβ production. They also activated AMPK in microglia — the brain's immune cells — suppressing neuroinflammation and enhancing Aβ clearance. Together, these effects reduced plaque buildup and rescued memory deficits in mouse models, suggesting GLP-1RAs hold real therapeutic promise for Alzheimer's disease.
